Q-omics provides the consensus-scored SNORA2A profile across patient tissues and cancer cell-line models. SNORA2A expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SNORA2A is differentially expressed in 8, with the highest sampling consensus in BLCA. Additionally, SNORA2A RNA expression shows 17,175 significant gene co-expression associations, with the highest sampling consensus in DLBC. Together, these results highlight KIRC, BLCA, and DLBC as cancer lineages where SNORA2A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SNORA2A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SNORA2A survival associations across molecular data types. SNORA2A RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SNORA2A RNA expression–survival associations across cancer types. High SNORA2A expression shows unfavorable associations in KIRC and UVM, but favorable associations in BLCA, UCS, SKCM and BRCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SNORA2A RNA expression.
This table summarizes SNORA2A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for SNORA2A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SNORA2A shows higher tumor expression in BLCA, KIRC, COAD, CHOL, PRAD and READ. The BLCA box plot shows higher SNORA2A RNA expression in tumor versus normal tissue (log2 FC = +0.830, t-test p = .006).
This table shows molecular features associated with SNORA2A in patient tissues and cancer cell lines. In patient samples, SNORA2A shows the broadest associations at the RNA and protein expression levels, with DLBC recurring as the lineage with the largest associated feature set.
